776 completed, 175 terminated, 113 unknown, 101 recruiting. 590 Phase 2, 438 Phase 1, 139 Not applicable, 96 Phase 3, 12 Early Phase 1.
Follow Hodgkin Disease: new trials by email Literature Review of Hodgkin Disease trials Research Report on Hodgkin Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity 68Ga-Galmydar, PET/MRI, 18F-FDG - Lymphoma Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-01 | 2026-09-24 |
| Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma Proton Therapy (Adaptive) - Pediatric Solid Tumors, Rhabdomyosarcoma | Not applicable | Recruiting | St. Jude Children's Research Hospital | 100 | 2026-08-20 | 2026-08-21 |
| Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL Nivolumab, Doxorubicin Hydrochloride, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2026-08-19 | 2026-08-31 |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| CD45BE-HSPC + CART-45 Cells CART-45 cells, CD45BE-HSPC - B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation | Phase 1 | Recruiting | University of Pennsylvania | 42 | 2026-08-05 | 2026-08-10 |
| PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma 20 Gy Involved site radiotherapy, 30 Gy Involved site radiotherapy - Hodgkin Lymphoma | Phase 3 | Recruiting | Fondazione Italiana Linfomi - ETS | 518 | 2026-07-10 | 2026-08-27 |
| PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma PD-1+JAK1i, PD-1 - Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 112 | 2026-06-30 | 2026-06-11 |
| Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma High Intensity Interval Training (HIIT) - Hodgkin Lymphoma | Not applicable | Recruiting | St. Jude Children's Research Hospital | 20 | 2026-06-08 | 2026-06-10 |
| Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies Fludarabine, TGFBR2 KO CAR27/IL-15 NK cells, Cyclophosphamide - Lymphoid, Hodgkin Lymphoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 60 | 2026-05-28 | 2026-09-08 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-05-08 | 2026-07-28 |
| Proton Therapy for Mediastinal Lymphoma (PROMLY) Proton therapy - Mediastinal Lymphoma, Hodgkin Disease Lymphoma | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 139 | 2026-05-01 | 2026-09-14 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Halt Aging in Survivors of Blood Cancers Behavioral Coaching Intervention, Virtual Exercise Platform - Hematological Malignancy, Leukemia | Not applicable | Recruiting | University of Nebraska | 180 | 2026-04-09 | 2026-07-01 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF - Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 42 | 2026-03-04 | 2026-04-03 |
| A Phase I Study of JLM019 Injection JLM019 Injection - Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 115 | 2026-01-13 | 2026-06-03 |
Showing 20 of 1301. Sign in to see all of them.
Lymphoma, Non-Hodgkin (730) · Lymphoma (514) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (472) · Leukemia, Lymphocytic, Chronic, B-Cell (463) · Lymphoma, Large B-Cell, Diffuse (399) · Multiple Myeloma (391) · Lymphoma, Mantle-Cell (384) · Lymphoma, Follicular (383) · Leukemia, Myeloid, Acute (349) · Burkitt Lymphoma (346) · Lymphoma, B-Cell, Marginal Zone (343) · Lymphoma, Large-Cell, Immunoblastic (318) · Myelodysplastic Syndromes (289) · Leukemia (272)
Hemic and Lymphatic Diseases (1300) · Immune System Diseases (1298) · Immunoproliferative Disorders (1298) · Neoplasms by Histologic Type (1298) · Lymphatic Diseases (1297) · Lymphoproliferative Disorders (1259) · Neoplasms (1218) · Lymphoma (787) · Hematologic Diseases (679) · Pathological Conditions, Signs and Symptoms (616) · Pathologic Processes (601) · Disease Attributes (585) · Leukemia, Lymphoid (547) · Chronic Disease (518) · Leukemia, B-Cell (462)
Cyclophosphamide (193) · fludarabine phosphate (123) · Peripheral Blood Stem Cell Transplantation (107) · Etoposide (106) · Mycophenolic Acid (95) · Filgrastim (92) · Doxorubicin (85) · Whole-Body Irradiation (84) · Tacrolimus (81) · Brentuximab Vedotin (80) · Melphalan (78) · Busulfan (75) · Radiotherapy (74) · fludarabine (68) · Cyclosporine (67)
National Cancer Institute (NCI) (79) · Fred Hutchinson Cancer Center (60) · M.D. Anderson Cancer Center (50) · Memorial Sloan Kettering Cancer Center (47) · City of Hope Medical Center (35) · St. Jude Children's Research Hospital (26) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (23) · Baylor College of Medicine (22) · Masonic Cancer Center, University of Minnesota (21) · Case Comprehensive Cancer Center (19) · University of Cologne (18) · Dana-Farber Cancer Institute (17) · Mayo Clinic (17) · Seagen Inc. (16) · Northwestern University (15)
United States (944) · Italy (90) · France (69) · Germany (65) · Canada (57) · United Kingdom (52) · Spain (39) · China (35) · Belgium (32) · Australia (31) · Netherlands (26) · Russia (26) · Poland (23) · Israel (22) · Czechia (18)
Brenda Sandmaier (12) · Ajay Gopal (8) · Anas Younes, MD (8) · Andreas Engert, Prof. (6) · Sandra J. Horning, MD (6) · Alex F Herrera (5) · Armando Santoro, MD (5) · David Maloney (5) · Helen Heslop, MD (5)
PMID 40135712, PMID 32499241, PMID 37505794, PMID 22510871, PMID 30010775, PMID 32596842, PMID 33951890, PMID 37722357, PMID 40156952, PMID 41074963, PMID 20661232, PMID 21454450, PMID 24239220, PMID 25311218, PMID 30262660, PMID 31112476, PMID 31395089, PMID 31401903, PMID 33062947, PMID 36541117, PMID 38640255, PMID 39620432, PMID 39774828, PMID 39908567, PMID 40668662, PMID 41698326, PMID 10204198, PMID 10552943, PMID 10764422, PMID 11172953, PMID 11410496, PMID 11709567, PMID 12171484, PMID 12377653, PMID 12525530, PMID 12972528, PMID 1403051, PMID 14630682, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15107815, PMID 15112270, PMID 15386331, PMID 15459300, PMID 15570084, PMID 15657404, PMID 15817673, PMID 15837968, PMID 15936157
P30CA015704 (31), P30CA033572 (20), P30CA006973 (13), P30CA043703 (12), P01CA018029 (10), P30CA015083 (10), P30CA022453 (9), U10CA032102 (9), 2023 (8), P01CA078902 (8), P30CA016672 (8), P30CA072720 (8), P01CA015396 (7), U10CA031946 (7), 2015 (6)